VEGFA and hypertensive disorder: Numerous studies have indicated that hypertension and cardiovascular disease at baseline are crucial predictors of major adverse cardiac events (congestive heart failure, cardiovascular death, myocardial infarction) after the VEGF-TKI sunitinib therapy [29,98,123].